Gritstone bio is developing next-generation vaccines for cancer. Gritstone’s approach seeks to generate potent and durable immune responses by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens.
In October 2024, Gritstone bio took action to preserve value and strengthen capital by voluntarily filing for Chapter 11 relief.
With support from a strong investor, the company emerged in April 2025 as a leaner organization focused solely on the research & development of its cutting-edge oncological technologies.